Full‐length visfatin levels are associated with inflammation in women with polycystic ovary syndrome

Eur J Clin Invest 2012; 42 (3): 321–328

[1]  A. Malamitsi‐Puchner,et al.  Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. , 2010, Fertility and sterility.

[2]  E. Çakal,et al.  Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. , 2010, Fertility and sterility.

[3]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[4]  Ş. Kirazlı,et al.  Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. , 2010, Reproductive biomedicine online.

[5]  A. Schutte,et al.  Ethnic‐specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function , 2009, Obesity.

[6]  A. Rizvi.  Cytokine Biomarkers, Endothelial Inflammation, and Atherosclerosis in the Metabolic Syndrome: Emerging Concepts , 2009, The American journal of the medical sciences.

[7]  Dong Liu,et al.  Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans , 2009, Clinical endocrinology.

[8]  R. Gambino,et al.  Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[9]  G. Rini,et al.  Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. , 2009, Fertility and sterility.

[10]  E. Akbay,et al.  Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance , 2009, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[11]  Y. Liu,et al.  Correlation of circulating full‐length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross‐sectional study , 2008, Clinical endocrinology.

[12]  E. Diamanti-Kandarakis,et al.  Plasma visfatin levels in normal weight women with polycystic ovary syndrome. , 2008, European journal of internal medicine.

[13]  T. Brzozowski,et al.  Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[14]  M. Fasshauer,et al.  Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. , 2008, Clinical science.

[15]  M. Blüher,et al.  Molecular characteristics of serum visfatin and differential detection by immunoassays. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  N. Kohno,et al.  Circulating visfatin level is correlated with inflammation, but not with insulin resistance , 2007, Clinical endocrinology.

[17]  E. Tsai,et al.  Increased plasma visfatin concentrations in women with polycystic ovary syndrome. , 2007, Fertility and sterility.

[18]  M. Górska,et al.  Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. , 2007, Human reproduction.

[19]  M. Elisaf,et al.  Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome , 2007, Journal of endocrinological investigation.

[20]  S. Tonstad,et al.  Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary Atherosclerosis: Possible Role in Inflammation and Plaque Destabilization , 2007, Circulation.

[21]  H. Tilg,et al.  Visfatin , an Adipocytokine with Proinflammatory and Immunomodulating Properties 1 , 2007 .

[22]  Bounleut Phanavanh,et al.  Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. , 2007, The Journal of clinical endocrinology and metabolism.

[23]  H. Randeva,et al.  Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. , 2006, The Journal of clinical endocrinology and metabolism.

[24]  R. Azziz,et al.  Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. , 2006, Fertility and sterility.

[25]  E. Diamanti-Kandarakis,et al.  Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. , 2006, Human reproduction.

[26]  R. Busse,et al.  Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin , 2006, Diabetologia.

[27]  J. Gómez-Reino,et al.  Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[28]  Shyi-Jang Shin,et al.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. , 2006, The Journal of clinical endocrinology and metabolism.

[29]  M. Fasshauer,et al.  Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. , 2005, Diabetes.

[30]  Ricardo Azziz,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745–2749 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected , 2022 .

[31]  M. McCarthy,et al.  Metabolic Cardiovascular Disease Risk Factors in Women with Self-Reported Symptoms of Oligomenorrhea and/or Hirsutism: Northern Finland Birth Cohort 1966 Study , 2004 .

[32]  J. Marshall,et al.  Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. , 2004, The Journal of clinical investigation.

[33]  M. McCarthy,et al.  Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. , 2004, Human reproduction.

[34]  M. McCarthy,et al.  Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. , 2004, The Journal of clinical endocrinology and metabolism.

[35]  M. McCarthy,et al.  Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. , 2003, The Journal of clinical endocrinology and metabolism.

[36]  I. Vauhkonen,et al.  Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. , 2000, Human reproduction.

[37]  J. Levy,et al.  Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program , 1998, Diabetes Care.

[38]  A. Dunaif,et al.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.

[39]  K. Segal,et al.  Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome , 1989, Diabetes.

[40]  P. Rantakallio,et al.  Groups at risk in low birth weight infants and perinatal mortality. , 1969, Acta paediatrica Scandinavica.